Article Data

  • Views 1554
  • Dowloads 157

Original Research

Open Access

PRESERVATION OF ERECTILE FUNCTION BY STATINS IN A RAT MODEL OF ERECTILE DYSFUNCTION INDUCED BY HYPERCHOLESTEROLEMIA

  • Bong Hee Park1
  • Dong Seok Han1
  • Seung Mo Yuk1
  • Chang Shik Youn1
  • Eun Bi Kwon2
  • Ki Cheol Park3
  • Hoon Jang1

1Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

2Korea Bio Medical Science Institute, Seoul, Republic of Korea

3Clinical Research Institute, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Republic of Korea

DOI: 10.15586/jomh.v16i1.194 Vol.16,Issue 1,January 2020 pp.27-40

Published: 09 January 2020

*Corresponding Author(s): Hoon Jang E-mail: urjang@gmail.com

Abstract

Background and objective

To assess the effects of hypercholesterolemia (HC) on the quality of erections and to evaluate the effects of stain therapy in a rat model of erectile dysfunction (ED) induced by HC.

Material and methods

Sprague–Dawley rats were randomly divided into three groups (n=12 in each): control, HC, and HC with simvastatin treatment (HC+SS). The control was fed a normal chow diet, and the HC and HC+SS were fed a high-fat and high-cholesterol diet for 12 weeks. The HC+SS received simvastatin once daily via oral gavage for 12 weeks. Subsequently, the intraperitoneal glucose tolerance test (IPGTT), intra-cavernous pressure and mean arterial pressure, lipid profiles, expression of endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS), oxidative stress (8-hydroxy-2-deoxygua-nosine, 8-OHdG level), serum testosterone levels, and the ratio of collagen fibers (CF) and smooth muscle (SM) were evaluated in the serum and corpora tissue.

Results

IPGTT was not different among all groups. The HC showed markedly lower erectile parameters than the control. In contrast, the HC+SS showed preserved erectile function, improved lipid profiles, increased eNOS and nNOS, decreased oxidative stress, and minimized change in SM/CF ratio.

Conclusions

Our results suggest that oxidative stress damage by HC may cause ED and that statin therapy may have beneficial effects on preserving erectile function by improving lipid profiles and minimizing dam-age caused by oxidative stress.

Keywords

erectile dysfunction; hypercholesterolemia; statin

Cite and Share

Bong Hee Park,Dong Seok Han,Seung Mo Yuk,Chang Shik Youn,Eun Bi Kwon,Ki Cheol Park,Hoon Jang. PRESERVATION OF ERECTILE FUNCTION BY STATINS IN A RAT MODEL OF ERECTILE DYSFUNCTION INDUCED BY HYPERCHOLESTEROLEMIA. Journal of Men's Health. 2020. 16(1);27-40.

References

1. Vrentzos GE, Paraskevas KI, Mikhailidis DP. Dyslipidemia as a risk factor for erectile d ysfunction. Curr Med Chem 2007;14(16): 1765–70. https://doi.org/10.2174/09298670778 1058931

2. Kim SC, Kim IK, Seo KK, Baek KJ, Lee MY. Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res 1997;25(5):341–6. https://doi.org/10.1007/BF01294663

3. Musicki B, Liu T, Strong T, et al. Low-fat diet and exercise preserve eNOS regulation and endo-thelial function in the penis of early atheroscle-rotic pigs: a molecular analysis. J Sex Med 2008;5(3):552–61. https://doi.org/10.1111/j. 1743-6109. 2007.00731.x

4. Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005;517(3):224–31. https://doi.org/10.1016/j. ejphar.2005.05.012

5. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med 2014;11(7):1626–35. https://doi.org/10.1111/jsm.12521

6. Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a sys-tematic review and meta-analysis. Asian J Androl 2014;16(3):461–6. https://doi.org/10.4103/1008-682X. 123678

7. Cui Y, Zong H, Yan H, Zhang Y. The effect of statins on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2014;11(6):1367–75. https://doi.org/10.1111/jsm.12497

8. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004;172(1): 255–8. https://doi.org/10.1097/01.ju.0000132368. 10458.66

9. Trivedi D, Kirby M, Wellsted DM, et al. Can sim-vastatin improve erectile function and health-related quality of life in men aged >/=40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2013;111(2):324–33. https://doi.org/ 10.1111/j.1464-410X.2012.11241.x

 10. Rizvi K, Hampson JP, Harvey JN. Do lipid-low-ering drugs cause erectile dysfunction? A system-atic review. Fam Pract 2002;19(1):95–8. https://doi.org/10.1093/fampra/19.1.95

 11. Carvajal A, Macias D, Sainz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring sys-tems. Drug Safety 2006;29(2):143–9. https://doi. org/10.2165/00002018-200629020-00004

 12. Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Safety 2009;32(7):591–7. https://doi.org/10.2165/00002018-200932070-00005

 13. Jang H, Bae WJ, Kim SJ, et al. The herbal for-mula KH-204 is protective against erectile dys-function by minimizing oxidative stress and improving lipid profiles in a rat model of erectile dysfunction induced by hypercholesterolaemia. BMC Complement Altern Med 2017;17(1):129. https://doi.org/10.1186/s12906-017-1588-4

 14. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001;87(9):838–45. https://doi.org/10.1046/j.1464-410x. 2001.02211.x

 15. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120(2):151–7. https://doi.org/10.1016/j. amjmed.2006.06.010

 16. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: relevance and role of phosphodies-terase type-5 inhibitors and statins. J Sex Med 2008;5(5):1066–78. https://doi.org/10.1111/

j. 1743-6109. 2008.00783.x

 17. Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO, Carson CC, 3rd, . Experimental hyper-cholesterolemia in rabbits induces cavernosal ath-erosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994;151(1):198–205. https://doi.org/10.1016/S0022-5347(17)34916-9

 18. Behr-Roussel D, Bernabe J, Compagnie S, et al. Distinct mechanisms implicated in atherosclero-sis-induced erectile dysfunction in rabbits. Atherosclerosis 2002;162(2):355–62. https://doi. org/10.1016/S0021-9150(01)00740-7

 19. Kim SC, Seo KK, Kim HW, Lee MY. The effects of isolated lipoproteins and triglyceride, combined oxidized low density lipoprotein (LDL) plus tri-glyceride, and combined oxidized LDL plus high density lipoprotein on the contractile and relax-ation response of rabbit cavernous smooth muscle. Int J Androl 2000;23 Suppl 2:26–9. https://doi. org/10.1046/j.1365-2605.2000.00007.x

2 0. Musicki B, Liu T, Lagoda GA, et al. Hypercholesterolemia-induced erectile dysfunc-tion: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxi-dase. J Sex Med 2010;7(9):3023–32. https://doi. org/10.1111/j.1743-6109.2010.01880.x

 21. Lubos E, Handy DE, Loscalzo J. Role of oxida-tive stress and nitric oxide in atherothrombosis. Front Biosci 2008;13:5323–44. https://doi.org/ 10.2741/3084

 22. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension.Histochem Cell Biol 2004;122(4):339–52. https://doi.org/10.1007/s00418-004-0696-7

 23. Park EJ, Chun JN, Kim SH, et al. Schisandrin B suppresses TGFbeta1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem Pharmacol 2012;83(3):378–84. https://doi.org/ 10.1016/j.bcp.2011.11.002

 24. Chen P, Pang S, Yang N, et al. Beneficial effects of schisandrin B on the cardiac function in mice model of myocardial infarction. PLoS One 2013;8(11):e79418. https://doi.org/10.1371/journal. pone.0079418

 25. Chun JN, Kim SY, Park EJ, et al. Schisandrin B suppresses TGFbeta1-induced stress fiber forma-tion by inhibiting myosin light chain phosphory-lation. J Ethnopharmacol 2014;152(2):364–71. https://doi.org/10.1016/j.jep.2014.01.024

 26. Chen N, Ko M. Schisandrin B-induced glutathi-one antioxidant response and cardioprotection are mediated by reactive oxidant species production in rat hearts. Biol Pharm Bull 2010;33(5):825–9. https://doi.org/10.1248/bpb.33.825

 27. Chiu PY, Ko KM. Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells. BioFactors 2006;26(4):221–30. https://doi.org/10.1002/biof.5520260401

 28. Thandavarayan RA, Giridharan VV, Arumugam S, et al. Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS One 2015;10(3):e0119214. https://doi.org/10.1371/journal.pone.0119214

 29. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90(1):21–8. https://doi.org/10.1161/hh0102.102330

 30. Gotto AM. Statin therapy: where are we? Where do we go next? Am J Cardiol 2001;87(5a):13b–8b. https://doi.org/10.1016/S0002-9149(01)01450-3

 31. Guijarro C, Blanco-Colio LM, Ortego M, et al.

3- Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83(5):490–500. https://doi.org/10.1161/01. RES.83.5.490

 32. Liu L, Moesner P, Kovach NL, et al. Integrin-dependent leukocyte adhesion involves geranylger-anylated protein(s). J Biol Chem 1999;274(47): 33334–40. https://doi.org/10.1074/jbc.274.47. 33334

 33. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investiga-tors. N Engl J Med 1996;335(14):1001–9. https://doi.org/10.1056/NEJM199610033351401

 34. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrino-lytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998;83(7):683–90. https://doi.org/10.1161/01. RES.83.7.683

 35. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholes-terolemic mice. Stroke 2000;31(10):2442–9. https://doi.org/10.1161/01.STR.31.10.2442

 36. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hyperten-sion via reduced production of reactive oxygen species. Hypertension 2001;37(6):1450–7. https://doi.org/10.1161/01.HYP.37.6.1450

 37. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23(5):729–36. https://doi. org/10.1161/01.ATV.0000063385.12476.A7

 38. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87(4):1451–8. https://doi. org/10.1210/jcem.87.4.8412

 39. Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010;7(4 Pt 1):1547–56. https://doi.org/10.1111/

j. 1743-6109.2009.01698.x

 40. Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterol-emic men? A randomized double-blind trial. Psychoneuroendocrinology 2003;28(2):181–94. https://doi.org/10.1016/S0306-4530(02)00014-8

 41. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:

57. https://doi.org/10.1186/ 1741-7015-11-57

 42. Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med 2013;11:58. https://doi.org/10.1186/1741-7015-11-58

 43. Martinez-Martos JM, Arrazola M, Mayas MD, Carrera-Gonzalez MP, Garcia MJ, Ramirez-Exposito MJ. Diet-induced hypercholes-terolemia impaired testicular steroidogenesis in mice through the renin-angiotensin system. Gen Comp Endocrinol 2011;173(1):15–19. https://doi. org/ 10.1016/j.ygcen.2011.04.015

 44. Tanaka M, Nakaya S, Kumai T, Watanabe M, Matsumoto N, Kobayashi S. Impaired testicular function in rats with diet-induced hypercholester-olemia and/or streptozotocin-induced diabetes mellitus. Endocr Res 2001;27(1–2):109–17. https://doi.org/10.1081/ERC-100107174

 45. Feng Y, Zhu Y, Chen X, Sha J, Fan L, Chen Q. Effects of diet-induced hypercholester-olemia on testosterone-regulated protein expres-sion in mice liver. J Nanosci Nanotechnol 2005;5(8):1273–6. https://doi.org/10.1166/jnn. 2005.204

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top